Get started
Author

John-Joseph Borg

Observed names: Borg, John-Joseph, John J Borg, John J. Borg, John Joseph Borg
Observed institutions: University of Rome Tor Vergata, University of London, European Medicines Agency, St George's, University of London, University of Malta, Israel Medical Association, Universitätsmedizin Göttingen, Centro Médico Sanitas Málaga, University of Göttingen
ORCID: 0000-0003-2862-8839
Observed ORCID: 0000-0003-2862-8839
OpenAlex ID: A5102875544
Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?
2011 · John-Joseph Borg, George Aislaitner, et al. · Drug Safety · 105
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
2023 · Daniela Melchiorri, Sara Merlo, et al. · Frontiers in Pharmacology · 75
PDF
Aducanumab for Alzheimer’s disease: A regulatory perspective
2021 · Robert Nisticò, John Joseph Borg · Pharmacological Research · 65
PDF
Regulatory evaluation of Glybera in Europe — two committees, one mission
2013 · Daniela Melchiorri, Luca Pani, et al. · Nature Reviews Drug Discovery · 60
PDF
In support of the European Union biosimilar framework
2012 · Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP), Christian K Schneider, et al. · Nature Biotechnology · 38
PDF
European Union pharmacovigilance capabilities: potential for the new legislation
2015 · John Joseph Borg, Amy Tanti, et al. · Therapeutic Advances in Drug Safety · 35
Novel approaches to the stratified management of knee osteoarthritis
2025 · Nicholas R. Fuggle, Roland Chapurlat, et al. · Nature Reviews Rheumatology · 33
PDF
Treatment of Leber’s hereditary optic neuropathy: An overview of recent developments
2020 · Marta Zuccarelli, Janis Vella-Szijj, et al. · European Journal of Ophthalmology · 33
Quality Issues Identified During the Evaluation of Biosimilars by the European Medicines Agency’s Committee for Medicinal Products for Human Use
2017 · Mark Cilia, Sol Ruiz, et al. · AAPS PharmSciTech · 27
PDF
A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects
2020 · Carla Petrella, Stefano Farioli-Vecchioli, et al. · Current Neuropharmacology · 25
PDF
Independent Academic Data Monitoring Committees for Clinical Trials in Cardiovascular and Cardiometabolic Diseases
2017 · Gerasimos S. Filippatos, Pieter de Graeff, et al. · European Journal of Heart Failure · 23
PDF
Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU
2021 · Dianne Butler, Katarina Vucic, et al. · Expert Opinion on Drug Safety · 18
Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products
2009 · John Joseph Borg, Jean-Louis Robert, et al. · Journal of Pharmacy & Pharmaceutical Sciences · 18
PDF
An Exploratory Study of the Impact of COVID-19 Vaccine Spontaneous Reporting on Masking Signal Detection in EudraVigilance
2023 · Benjamin Micallef, Jean-Michel Dogné, et al. · Drug Safety · 16
Medication errors through a national pharmacovigilance database approach: A study for Malta
2013 · Amy Tanti, Miriam Camilleri, et al. · International Journal of Risk & Safety in Medicine · 13
Multimodal management as requirement for the clinical use of anticachexia drugs - a regulatory and a clinical perspective
2015 · John J. Borg, Stefan D. Anker, et al. · Current Opinion in Supportive and Palliative Care · 12
Reflections on Decisions Taken on Well Established Use Medicinal Products by EU Regulators and the ECJ: A Pharmaceutical Regulatory Perspective
2014 · John Joseph Borg, Andrea Laslop, et al. · Scientia Pharmaceutica · 11
PDF
Improving the data quality of spontaneous ADR reports: a practical example from Malta
2021 · Marta Zuccarelli, Benjamin Micallef, et al. · Expert Opinion on Drug Safety · 9
The changing landscape of treatment options in childhood acute lymphoblastic leukaemia
2022 · Benjamin Micallef, Robert Nisticò, et al. · Drug Discovery Today · 7
A review of the National pharmacovigilance system in Malta – implementing and operating a pharmacovigilance management system
2016 · Amy Tanti, Benjamin Micallef, et al. · Expert Opinion on Drug Safety · 6
Reply to In support of the European Union biosimilar framework
2012 · Working Party on Similar Biological (Biosimilar) Medicinal Products (BMWP), Christian K Schneider, et al. · Nature Biotechnology · 5
PDF
QT shortening: a proarrhythmic safety surrogate measure or an inappropriate indicator of it?
2022 · Amy Tanti, Benjamin Micallef, et al. · Current Medical Research and Opinion · 4
Opinions of Maltese doctors and pharmacists on medication errors
2017 · Amy Tanti, Miriam Camilleri, et al. · International Journal of Risk & Safety in Medicine · 4
Licensing of Generic Medicines, are there Any Challenges Left? A Pharmaceutical Regulatory Perspective
2014 · John Joseph Borg, Paolo Tomasi, et al. · Scientia Pharmaceutica · 4
PDF
The European Innovation Network as a hub for medicines innovation in Europe
2024 · Eleonora Agricola, Caroline Auriche-Benichou, et al. · Nature Reviews Drug Discovery · 3
Works count: 44
Citation count: 664
H-index: 14
I10-index: 17
Year
Topic
Type